Lista de obras -

Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.

artículo científico publicado en 2014

Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients

artículo científico publicado en 2014

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations

artículo científico publicado en 2018

Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response

artículo científico publicado en 2022

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients

artículo científico publicado en 2012

Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.

artículo científico publicado en 2015

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

artículo científico publicado en 2015

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?

artículo científico publicado en 2015

Early initiation of antiretroviral therapy: debate over?

artículo científico publicado en 2016

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

artículo científico publicado en 2009

Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

scientific article published on 09 May 2016

HIV-1 p24 and CD4+ T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients.

artículo científico publicado en 2016

Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.

artículo científico publicado en 2015

Immune activation throughout a boosted darunavir monotherapy simplification strategy.

artículo científico publicado en 2014

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes

artículo científico publicado en 2013

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients

artículo científico publicado en 2011

Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?

artículo científico publicado en 2020

Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.

artículo científico publicado en 2014

Mesenchymal stromal cells in Human Immunodeficiency Virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial

scientific article published on 02 December 2020

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

scientific article published in PLoS ONE

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.

artículo científico publicado en 2016

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract

artículo científico publicado en 2015

Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.

artículo científico publicado en 2007

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.

artículo científico publicado en 2008

Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.

artículo científico publicado en 2013

Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. ⬇️

artículo científico publicado en 2015

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.

artículo científico publicado en 2013

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

artículo científico publicado en 2007

Viral kinetics in semen with different antiretroviral families in treatment-naïve HIV-infected patients: a randomized trial.

artículo científico publicado en 2017

Lista de obras de

Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.

Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations

Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients

Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?

Early initiation of antiretroviral therapy: debate over?

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

HIV-1 p24 and CD4+ T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients.

Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.

Immune activation throughout a boosted darunavir monotherapy simplification strategy.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients

Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?

Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.

Mesenchymal stromal cells in Human Immunodeficiency Virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract

Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.

Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.

Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy. ⬇️

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

Viral kinetics in semen with different antiretroviral families in treatment-naïve HIV-infected patients: a randomized trial.